Question · Q4 2025
Alec asked if the ONSTRIDE 1 and 2 studies (Pitolisant HD) had begun enrolling patients, noting the absence of updates on ClinicalTrials.gov. He also sought clarification on whether the OpEx expenditure related to settlements and litigation was primarily within the General and Administrative line item and the expected run rate moving forward.
Answer
Dr. Kumar Budur, Chief Medical and Scientific Officer, confirmed that sites for ONSTRIDE 1 and 2 studies began initiation towards the end of 2025, with ClinicalTrials.gov updates expected within 21-30 days of the first subject enrollment. He stated that sites are currently preparing to enroll patients. Sandip Kapadia, CFO and Chief Administrative Officer, confirmed that most litigation and settlement expenses were indeed under G&A, noting that some are one-time while others will continue as the litigation process proceeds.
Ask follow-up questions
Fintool can predict
HRMY's earnings beat/miss a week before the call